Highlights from the 77th Scientific Sessions of the American Diabetes Association


  • Caroline Day Visiting Fellow, Diabetes Group, Aston University, Birmingham B4 7ET, UK




American Diabetes Association, 77th Scientific Sessions Abstracts. Diabetes 2017;66(Suppl 1):A1–A830.

American Diabetes Association, 77th Scientific Sessions. Late Breaking Abstracts. Diabetes 2017; 66(Suppl 1A):LB1–LB123.

American Diabetes Association. Accessing Scientific Sessions webcasts 2017. https://professional.diabetes.org/webcasts-ss2017/purchase-scientific-sessions-webcasts

Marso SP, McGuire DK, Zinman B, et al, for the DEVOTE Study Group. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017 June 12. http://dx.doi.org/1056/NEJMoa1615692

Petrie JR, Chatuverdi N, Ford I, et al, for the REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet 2017;5:597-609. http://dx.doi.org/10.1016/S2213-8587(17)30194-8

Neal B, Perkovic V, Mahaffey KW, et al, for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–57. http://dx.doi.org/10.1056/NEJMoa1611925

Kosiborod M, Cavender MA, Fu AZ, et al, for the CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation May 2017;136:249–59. http://dx.doi.org/10.1161/CIRCULATIONAHA.117.029190






Meeting Reports